Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

How to form the fibrillary structure using beta-amyloid peptides? | LifeTein Peptide Blog

Aβ-(1–42) was dissolved to 1 mM in 100% hexafluoroisopropanol, hexafluoroisopropanol was removed under vacuum, and the peptide was stored at −20 °C. For the aggregation protocols, the peptide was first resuspended in dry Me2SO (DMSO) to 5 mM. For oligomeric co

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Aβ-(1–42) was dissolved to 1 mM in 100% hexafluoroisopropanol, hexafluoroisopropanol was removed under vacuum, and the peptide was stored at −20 °C. For the aggregation protocols, the peptide was first resuspended in dry Me2SO (DMSO) to 5 mM. For oligomeric conditions, F-12 (without phenol red) culture media was added to bring the peptide to a final concentration of 100 μM, and the peptide was incubated at 4 °C for 24 h. For fibrillar conditions, 10 mM HCl was added to bring the peptide to a final concentration of 100 μM, and the peptide was incubated for 24 h at 37 °C.

ADDLS, amyloid-derived diffusible ligands.

Preparing human islet amyloid polypeptide (hIAPP), also known as amylin, can be challenging due to its hydrophobic amino acid residues.

Here’s an improved method for dissolving lyophilized hIAPP:

Begin by dissolving lyophilized hIAPP in 80% (v/v) HFIP containing 10 mM HCl. This step ensures complete dissolution. The CD spectrum indicates the presence of a stable alpha-helical conformation, which remains so for several days.

Next, remove the HFIP by lyophilization, leaving behind lyophilized hIAPP.

Re-dissolve the lyophilized hIAPP in 10 mM HCl, and eliminate any insoluble components by ultracentrifugation.

The resulting hIAPP solution in 10 mM HCl is ready for immediate use in experiments.

To initiate the formation of hIAPP fibrils, introduce the stock solution into the reaction buffer. Conditions for fibril formation were optimized under two pH conditions:

Low pH: Utilize 25 uM hIAPP in 10 mM HCl, with varying concentrations of HFIP.

Neutral pH: Employ 25 uM hIAPP in a 50 mM sodium phosphate buffer at pH 7.0, with varying concentrations of HFIP.

Incubate these samples at 25 °C for several hours.

Reference: JOURNAL OF BIOLOGICAL CHEMISTRY 23965, JULY 8, 2011 VOLUME 286 NUMBER 27

Aducanumab is a human monoclonal antibody that has been studied for the treatment of Alzheimer’s disease.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Clinical Trials and Research

Several clinical trials have explored the use of PADRE in cancer vaccines. For instance, vaccines targeting Mucin 1 (MUC1), a glycoprotein overexpressed in many cancers, have shown promising results when combined with PADRE. These vaccines have demonstrated the ability to elicit strong immune responses, including the production of antibodies against cancer-specific antigens.

Source: lifetein.com ↗

Live-Cell Imaging and Internalization Studies

FAM-labeled peptides are indispensable tools for tracking cellular uptake and intracellular trafficking. For example, FAM-conjugated ovalbumin peptide (Fam-ova, SIINFEKL) has been widely used to study MHC-I antigen presentation and visualize cytosolic antigen release via confocal microscopy. Similarly, FAM-labeled cell-penetrating peptides (e.g., TAT-derived conjugates) have enabled real-time monitoring of peptide internalization.

Source: lifetein.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to solubilize my synthetic peptides? #

Please refer to this FAQ for details: Handling and Storage of Synthetic Peptides. If the peptides are still cloudy, or turbid, you may have reached the limit of solubility. When the peptides are insoluble in the buffer, please try to sonicate, centrifuge, and lyophilize the peptide. Make sure to break the lyophilized lumps into a fine powder. Then try a small volume of a good agent 8M Urea, NMP, DMF, or DMSO to dissolve the peptide. Then dilute with water or your desired buffer. For peptides with Arg or LYs, you should try to lower the pH to 6 because the protonated amino acids will help solubility. Sonication and the following solvents may help with difficult peptides: 1) Begin with 100 % acetonitrile then dilute with water until 50% 2) Begin with 100% DMSO then dilute with water until 30 % 3) Dissolve it with 8M Urea 4) Dissolve it with 6 or 8 M Guanidine hydrochloride 5) 6M GuHCL, 0.05% TFA, pH2, 6) 100% TFA 7) 40% AcOH, 30%ACN, 30% water

Source: lifetein.com ↗
Storage reference

Storage Conditions

Store labeled peptides in opaque vials at -20°C to prevent photodegradation. Avoid repeated freeze-thaw cycles.

Source: lifetein.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →